Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Hemoglobin S, baseline hemoglobin/hematocrit,
研究概览
简要总结
Chronic blood transfusions are essential supportive care for sickle cell patients at high risk for morbidity and mortality due to stroke. These patients, however, are at risk for iron overload. In the investigator's comprehensive sickle cell center, the investigators support chronic transfusion with rapid manual partial exchange transfusions (RMPET) using a single access central line port. The investigators do not have a comprehensive adult sickle cell program but upon transition of patients the patients would be provided simple transfusion (ST) in an adult ambulatory infusion setting due to nursing acuity needed for RMPET. The investigators plan to study the institution's participants currently on chronic transfusion support and compare different transfusion modalities to better understand the effects from switching from RMPET to ST. To date, there are no such comparisons within and between sickle cell patients in the literature.
详细描述
II. Objective. Compare differences in RMPET versus ST.
III. Specific Aims:
- To compare key predictive hematologic factors (hematocrit, hemoglobin, hemoglobin S quantification, blood volume and alloantibodies) for relative risk of stroke utilizing two methods of blood transfusion therapy.
- To determine the nursing time to administer straight versus manual exchange transfusion therapy.
- To survey patient satisfaction for both procedures.
IV: Background/Significance:
Stroke occurs in 10% of Sickle Cell Disease (SCD) patients before the age of 20 Years. Current standard of care for secondary overt stroke prevention in patients with SCD is chronic red blood cell (RBC) transfusions. Stroke recurs in ~ 60% of patients without chronic RBC therapy and in ~ 20% of patients with chronic transfusion while maintaining a hemoglobin S percentage of less than 30%. Indefinite transfusion therapy is practiced as discontinuation after short-term or long-term prophylactic transfusions leads to recurrent overt strokes and more ensuing CNS damage, even with transition to hydroxyurea. Chronic transfusions also prevent initial stroke in high-risk patients identified by transcranial Doppler (TCD) ultrasound. The Stroke Prevention Study in Sickle Cell Disease (STOP) demonstrated a 92% stroke risk reduction among 63 of 130 children with abnormal TCD results. Rates of stroke declined significantly since implementing routine TCD screening and primary prophylactic transfusion therapy. The subsequent STOP 2 trial supports the use of chronic transfusion indefinitely because discontinuation resulted in an increased rate of abnormal TCD conversion and development of overt stroke. Discontinuing transfusions on the STOP 2 trial was also associated with a higher occurrence of silent cerebral infarcts, documented in 3 of 37 patients (8.1%) in the continued-transfusion group compared with 11 of 40 (27.5%) in the transfusion-halted group. More recent studies demonstrate that SCD patients are also at risk for silent cerebral infarcts. An association between worsening vasculopathy shown by magnetic resonance angiography and progressive overt and silent infarcts on magnetic resonance imaging has been found. More aggressive magnetic resonance imaging screening may be indicated and this could result in more patients with SCD treated with chronic transfusion.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Crossover
- 时间视角
- Prospective
入排标准
- 年龄范围
- 3 Years 至 25 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants between 3 and 25 years of age
- •Diagnosis of Hemoglobin SS or SBeta thalassemia
- •On chronic exchange for stroke prevention
- •Performance status: Lansky play score of 100%, and if over 16 years of age, Karnofsky=100%
排除标准
- •Participant has experienced more than one stroke and has a modified Rankin Scale of >
- •Diagnosis of Hemoglobin SC disease
- •Participants on chronic transfusion for priapism.
结局指标
主要结局
Hemoglobin S, baseline hemoglobin/hematocrit,
时间窗: Pre Infusion, lab collected monthly for one year thru study completion
Lab parameters pre-infusion for each method of transfusion
次要结局
- Hemoglobin S, end of transfusion hemoglobin/hematocrit, blood volume, alloantibodies,(Post Infusion, lab collected monthly for one year thru study completion)
研究者
Jennifer Keates, M.D.
Pediatric Oncologist / Hematologist
Chattanooga-Hamilton County Hospital Authority
